The analysis of antipsychotic drugs in human matrices using LC-MS(/MS)

Drug Testing and Analysis

Volumn 4, Issue 6, 2012, Pages 376-394

  Saar, Eva ^a   Beyer, Jochen ^a,b   Gerostamoulos, Dimitri ^a,b   Drummer, Olaf H ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b VICTORIAN INSTITUTE OF FORENSIC MEDICINE   (Australia)

Author keywords

Antipsychotic drugs; LC MS( MS); Method validation

Indexed keywords

CHEMICAL DETECTION; DRUG PRODUCTS; GAS CHROMATOGRAPHY; MASS SPECTROMETRY;

ANTIPSYCHOTIC DRUG; DETECTION AND QUANTIFICATIONS; GASCHROMATOGRAPHY-MASS SPECTROMETRY; HUMAN MATRIX; HUMAN SPECIMENS; LC-MS(/MS); LC-MS-MS; LC.MS/MS; LOW CONCENTRATIONS; METHOD VALIDATIONS;

LIQUID CHROMATOGRAPHY;

AMISULPRIDE; ARIPIPRAZOLE; BROMPERIDOL; BUSPIRONE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MELPERONE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERAZINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; UNINDEXED DRUG;

CEREBROSPINAL FLUID ANALYSIS; CHEMISTRY; DRUG BLOOD LEVEL; DRUG MONITORING; FREEZE THAWING; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SOLID PHASE EXTRACTION; URINALYSIS; VALIDATION PROCESS;

EID: 84863085374     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1337     Document Type: Review

References (98)

1. G. C. Alexander, S. A. Gallagher, A. Mascola, R. M. Moloney, R. S. Stafford. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol. Drug Saf. 2011, 20(2), 177.
2. S. S. Gill, S. E. Bronskill, S. L. Normand, G. M. Anderson, K. Sykor, K. Lam, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann. Intern. Med. 2007, 146(11), 775.
3. M. Smith, D. Hopkins, R. C. Peveler, R. I. Holt, M. Woodward, K. Ismail. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Brit. J. Psychiat. 2008, 192(6), 406.
4. W. A. Ray, C. P. Chung, K. T. Murray, K. Hall, C. M. Stein. Atypical antipsychotic drugs and the risk of sudden cardiac death. New Engl. J. Med. 2009, 360(3), 225.
5. G. Zhang, A. V. Terry Jr, M. G. Bartlett. Bioanalytical methods for the determination of antipsychotic drugs. Biomed. Chromatogr. 2008, 22(7), 671.
6. V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur. J. Drug Metab. Pharmacokinet. 1991, 16(4), 249.
7. F. T. Peters, H. H. Maurer. Bioanalytical method validation and its implications for forensic and clinical toxicology - A review. Accred. Qual. Assur. 2002, 7(11), 441.
8. V. P. Shah, K. K. Midha, J. W. Findlay, et al. Bioanalytical method validation - A revisit with a decade of progress. Pharm. Res. 2000, 17(12), 1551.
9. F. T. Peters, O. H. Drummer, F. Musshoff. Validation of new methods. Forensic Sci. Int. 2007, 165(2/3), 216.
10. G. Skopp. Postmortem Toxicology: Artifacts, in Wiley Encyclopedia of Forensic Science. John Wiley & Sons: Hoboken, New Jersey, USA, 2009.
11. A. Pelander, I. Ojanpera, S. Laks, I. Rasanen, E. Vuori. Toxicological screening with formula-based metabolite identification by liquid chromatography/time-of-flight mass spectrometry. Anal. Chem. 2003, 75(21), 5710.
12. S. Ojanpera, A. Pelander, M. Pelzing, I. Krebs, E. Vuori, I. Ojanpera. Isotopic pattern and accurate mass determination in urine drug screening by liquid chromatography/time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20(7), 1161.
13. M. Gergov, B. Boucher, I. Ojanpera, E. Vuori. Toxicological screening of urine for drugs by liquid chromatography/time-of-flight mass spectrometry with automated target library search based on elemental formulas. Rapid Commun. Mass Spectrom. 2001, 15(8), 521.
14. T. Arinobu, H. Hattori, M. Iwai, A. Ishii, T. Kumazawa, O. Suzuki, et al. Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 776(1), 107.
15. M. De Meulder, B. M. Remmerie, R. de Vries, L. L. Sips, S. Boom, E. W. Hooijschuur, et al. Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 870(1), 8.
16. M. Josefsson, R. Kronstrand, J. Andersson, M. Roman. Evaluation of electrospray ionisation liquid chromatography-tandem mass spectrometry for rational determination of a number of neuroleptics and their major metabolites in human body fluids and tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 789(1), 151.
17. T. Kumazawa, H. Seno, K. Watanabe-Suzuki, H. Hattori, A. Ishii, K. Sato, et al. Determination of phenothiazines in human body fluids by solid-phase microextraction and liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 2000, 35(9), 1091.
18. S. McClean, E. J. O'Kane, W. F. Smyth. Electrospray ionisation-mass spectrometric characterisation of selected anti-psychotic drugs and their detection and determination in human hair samples by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 2000, 740(2), 141.
19. C. Muller, S. Vogt, R. Goerke, A. Kordon, W. Weinmann. Identification of selected psychopharmaceuticals and their metabolites in hair by LC/ESI-CID/MS and LC/MS/MS. Forensic Sci. Int. 2000, 113(1-3), 415.
20. M. K. Nielsen, S. S. Johansen, P. W. Dalsgaard, K. Linnet. Simultaneous screening and quantification of 52 common pharmaceuticals and drugs of abuse in hair using UPLC-TOF-MS. Forensic Sci. Int. 2010, 196(1/3), 85.
21. D. Thieme, H. Sachs. Examination of a long-term clozapine administration by high resolution segmental hair analysis. Forensic Sci. Int. 2007, 166(2/3), 110.
22. W. Weinmann, C. Muller, S. Vogt, A. Frei. LC-MS-MS analysis of the neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol in hair obtained from psychiatric patients. J. Anal. Toxicol. 2002, 26(5), 303.
23. J. K. Aps, L. C. Martens. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci. Int. 2005, 150(2-3), 119.
24. J. Flarakos, W. Luo, M. Aman, D. Svinarov, N. Gerber, P. Vouros. Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry. J. Chromatogr. A 2004, 1026(1/2), 175.
25. M. Josefsson, M. Roman, E. Skogh, M. L. Dahl. Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J. Pharm. Biomed. Anal. 2010, 53(3), 576.
26. K. Nozaki, I. Osaka, H. Kawasaki, R. Arakawa. Application of on-line electrochemistry/electrospray/tandem mass spectrometry to a quantification method for the antipsychotic drug zotepine in human serum. Anal. Sci. 2009, 25(10), 1197.
27. J. Hasselstrom. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879(1), 123.
28. M. Kollroser, C. Schober. Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma. Rapid Commun. Mass Spectrom. 2002, 16(13), 1266.
29. W. Lindner, I. W. Wainer. Requirements for initial assay validation and publication in J. Chromatography B. J. Chromatogr. B Biomed. Sci. Appl. 1998, 707(1/2), 1.
30. M. Z. Huang, J. Z. Shentu, J. C. Chen, J. Liu, H. L. Zhou. Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. J. Zhejiang Univ. Sci. B 2008, 9(2), 114.
31. S. Nyberg, M. L. Dahl, C. Halldin. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995, 119(3), 345.
32. M. Aravagiri, S. R. Marder, K. H. Nuechterlein, M. J. Gitlin. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther. Drug Monit. 2003, 25(6), 657.
33. J. K. Darby, D. J. Pasta, L. Elfand, L. Dabiri, L. Clark, J. Herbert. Risperidone dose and blood level variability: Accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J. Clin. Psychopharmacol. 1997, 17(6), 478.
34. E. Spina, A. Avenoso, G. Facciola, M. Salemi, M. G. Scordo, M. Ancione, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001, 153(2), 238.
35. T. M. Annesley. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49(7), 1041.
36. R. Dams, M. A. Huestis, W. E. Lambert, C. M. Murphy. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom. 2003, 14(11), 1290.
37. M. Aravagiri, S. R. Marder. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J. Pharm. Biomed. Anal. 2001, 26(2), 301.
38. M. Aravagiri, S. R. Marder. Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. J. Mass Spectrom. 2000, 35(6), 718.
39. M. Berna, B. Ackermann, K. Ruterbories, S. Glass. Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 767(1), 163.
40. B. Cabovska, S. L. Cox, A. A. Vinks. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852(1/2), 497.
41. S. H. Cho, H. W. Lee, H. T. Im, W. S. Park, Y. W. Choi, J. H. Rew, et al. Rapid and highly sensitive liquid chromatography/electrospray ionization tandem mass spectrometry method for the quantitation of buspirone in human plasma: Application to a pharmacokinetic study. Rapid Commun. Mass Spectrom. 2006, 20(8), 1293.
42. M. H. Gschwend, P. Arnold, J. Ring, W. Martin. Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 831(1/2), 132.
43. M. Kollroser, G. Henning, R. Gatternig, C. Schober. HPLC-ESI-MS/MS determination of zuclopenthixol in a fatal intoxication during psychiatric therapy. Forensic Sci. Int. 2001, 123(2/3), 243.
44. M. Kubo, Y. Mizooku, Y. Hirao, T. Osumi. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 822(1/2), 294.
45. D. E. Moody, J. D. Laycock, W. Huang, R. L. Foltz. A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma. J. Anal. Toxicol. 2004, 28(6), 494.
46. R. V. Nirogi, V. N. Kandikere, M. Shukla, K. Mudigonda, S. Maurya, R. Boosi, et al. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. J. Pharm. Biomed. Anal. 2006, 41(3), 935.
47. K. J. Swart, F. C. Sutherland, G. H. van Essen, H. K. Hundt, A.F. Hundt. Determination of fluspirilene in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. J. Chromatogr. A 1998, 828(1/2), 219.
48. U. Gutteck, K. K. Rentsch. Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry. Clin. Chem. Lab. Med. 2003, 41(12), 1571.
49. M. Roman, R. Kronstrand, D. Lindstedt, M. Josefsson. Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS. J. Anal. Toxicol. 2008, 32(2), 147.
50. E. Saar, D. Gerostamoulos, O. H. Drummer, J. Beyer. Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. J. Mass Spectrom. 2010, 45(8), 915.
51. Z. Zhou, X. Li, K. Li, Z. Xie, Z. Cheng, W. Peng, et al. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2004, 802(2), 257.
52. B. Barrett, M. Holcapek, J. Huclova, V. Borek-Dohalsky, P. Fejt, B. Nemec, et al. Validated HPLC-MS/MS method for determination of quetiapine in human plasma. J. Pharm. Biomed. Anal. 2007, 44(2), 498.
53. M. Berna, R. Shugert, J. Mullen. Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 1998, 33(10), 1003.
54. B. M. Remmerie, L. L. Sips, R. de Vries, J. de Jong, A. M. Schothuis, E. W. Hooijschuur, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 783(2), 461.
55. E. Choong, S. Rudaz, A. Kottelat, D. Guillarme, J. L. Veuthey, C. B. Eap. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J. Pharm. Biomed. Anal. 2009, 50(5), 1000.
56. C. Kratzsch, F. T. Peters, T. Kraemer, A. A. Weber, H. H. Maurer. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J. Mass Spectrom. 2003, 38(3), 283.
57. H. A. Niederlander, E. H. Koster, M. J. Hilhorst, H. J. Metting, M. Eilders, B. Ooms, et al. High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on-line coupling of solid phase extraction with liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 834(1/2), 98.
58. M. Rittner, F. Pragst, W. R. Bork, J. Neumann. Screening method for seventy psychoactive drugs or drug metabolites in serum based on high-performance liquid chromatography--electrospray ionization mass spectrometry. J. Anal. Toxicol. 2001, 25(2), 115.
59. A. M. Verweij. Quantitative liquid chromatography, thermospray/tandem mass spectrometry (LC/TSP/MS/MS) analysis of some tranquilizers of the thixanthene group in whole-blood. J. Liq. Chromatogr. R. T. 1994, 17(19), 4099.
60. E. Saar, D. Gerostamoulos, O. H. Drummer, J. Beyer. Comparison of extraction efficiencies and LC-MS-MS matrix effects using LLE and SPE methods for 19 antipsychotics in human blood. Anal. Bioanal. Chem. 2009, 393(2), 727.
61. H. Kirchherr, W. N. Kuhn-Velten. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 843(1), 100.
62. J. Bhatt, G. Subbaiah, S. Singh. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Commun. Mass Spectrom. 2006, 20(14), 2109.
63. E. Chambers, D. M. Wagrowski-Diehl, Z. Lu, J. R. Mazzeo. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852(1/2), 22.
64. M. Jemal, Z. Ouyang, Y. Q. Xia. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr. 2010, 24(1), 2.
65. M. K. Nielsen, S. S. Johansen. Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 2009, 33(4), 212.
66. H. Sachs, P. Kintz. Recommendations for hair testing in forensic cases. Forensic Sci. Int. 2004, 145(2/3), 83.
67. T. Cairns, V. Hill, M. Schaffer, W. Thistle. Levels of cocaine and its metabolites in washed hair of demonstrated cocaine users and workplace subjects. Forensic Sci. Int. 2004, 145(2/3), 175.
68. T. Cairns, V. Hill, M. Schaffer, W. Thistle. Amphetamines in washed hair of demonstrated users and workplace subjects. Forensic Sci. Int. 2004, 145(2/3), 137.
69. T. Cairns, V. Hill, M. Schaffer, W. Thistle. Removing and identifying drug contamination in the analysis of human hair. Forensic Sci. Int. 2004, 145(2/3), 97.
70. M. Schaffer, V. Hill, T. Cairns. Morphine and 6-monoacetylmorphine in hair of heroin users: use of invalid extraction procedures generates erroneous conclusions. J. Anal. Toxicol. 2005, 29(1), 76.
71. M. I. Schaffer, W. L. Wang, J. Irving. An evaluation of two wash procedures for the differentiation of external contamination versus ingestion in the analysis of human hair samples for cocaine. J. Anal. Toxicol. 2002, 26(7), 485.
72. W. L. Wang, E. J. Cone. Testing human hair for drugs of abuse. IV. Environmental cocaine contamination and washing effects. Forensic Sci. Int. 1995, 70(1/3), 39.
73. R. B. Paulsen, D. G. Wilkins, M. H. Slawson, K. Shaw, D. E. Rollins. Effect of four laboratory decontamination procedures on the quantitative determination of cocaine and metabolites in hair by HPLC-MS. J. Anal. Toxicol. 2001, 25(7), 490.
74. F. Musshoff, B. Madea. New trends in hair analysis and scientific demands on validation and technical notes. Forensic Sci. Int. 2007, 165(2/3), 204.
75. C. Hoelzle, F. Scheufler, M. Uhl, H. Sachs, D. Thieme. Application of discriminant analysis to differentiate between incorporation of cocaine and its congeners into hair and contamination. Forensic Sci. Int. 2008, 176(1), 13.
76. M. J. Bogusz, K. D. Kruger, R. D. Maier, R. Erkwoh, F. Tuchtenhagen. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 1999, 732(2), 257.
77. K. Kassahun, E. Mattiuz, E. Nyhart Jr., B. Obermeyer, T. Gillespie, A. Murphy, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 1997, 25(1), 81.
78. E. Skogh, I. Sjodin, M. Josefsson, M. L. Dahl. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J. Clin. Psychopharm. 2011, 31(1), 4.
79. L. E. van Beijsterveldt, R. J. Geerts, J. E. Leysen, A. A. Megens, H. M. Van den Eynde, W. E. Meuldermans, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacol. (Berl.) 1994, 114(1), 53.
80. J. Kane, F. Canas, M. Kramer, L. Ford, C. Gassmann-Mayer, P. Lim, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. 2007, 90(1/3), 147.
81. N. Yasui-Furukori, M. Hidestrand, E. Spina, G. Facciola, M. G. Scordo, G. Tybring. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos. 2001, 29(10), 1263.
82. D. Remane, M. R. Meyer, D. K. Wissenbach, H. H. Maurer. Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: Validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs. Anal. Bioanal. Chem. 2011, 401(4), 1341.
83. C. Chin, Z. P. Zhang, H. T. Karnes. A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine. J. Pharm. Biomed. Anal. 2004, 35(5), 1149.
84. R. King, R. Bonfiglio, C. Fernandez-Metzler, C. Miller-Stein, T. Olah. Mechanistic investigation of ionization suppression in electrospray ionization. J. Am. Soc. Mass Spectrom. 2000, 11(11), 942.
85. B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75(13), 3019.
86. The World Anti-Doping Agency. Identification Criteria for Qualitative Assays, Document TD2003IDCR; 2010 [15 January 2012].
87. U.S. Department of Health and Human Services. Guidance for Industry: Mass Spectrometry for Confirmation of the Identity of Animal Drug Residues, Final Guidance. Available at: [15 January 2012].
88. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Validation concepts for pesticide residues in food of animal origin 2002/657/EC. 2002 [15 January 2012].
89. K. R. Allen. Interference by venlafaxine ingestion in the detection of tramadol by liquid chromatography linked to tandem mass spectrometry for the screening of illicit drugs in human urine. Clin. Toxicol. (Phila.) 2006, 44(2), 147.
90. H. H. Maurer. Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid. Anal. Bioanal. Chem. 2005, 381(1), 110.
91. M. J. Bogusz. Large amounts of drugs may considerably influence the peak areas of their coinjected deuterated analogues measured with APCI-LC-MS. J. Anal. Toxicol. 1997, 21(3), 246.
92. W. M. Chew, M. J. Xu, C. A. Cordova, H. H. Chow. Quantification of a cytochrome P450 3A4 substrate, buspirone, in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 844(2), 235.
93. D. Dadgar, P. E. Burnett. Issues in evaluation of bioanalytical method selectivity and drug stability. J. Pharm. Biomed. Anal. 1995, 14(1/2), 23.
94. R. Bonfiglio, R. C. King, T. V. Olah, K. Merkle. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13(12), 1175.
95. H. Seno, H. Hattori, A. Ishii, T. Kumazawa, K. Watanabe-Suzuki, O. Suzuki. High performance liquid chromatography/electrospray tandem mass spectrometry for phenothiazines with heavy side chains in whole blood. Rapid Commun. Mass Spectrom. 1999, 13(23), 2394.
96. Thomson Reuters (Healthcare) Inc. Microdemex® Healthcare Series, 1974-2010 Greenwood Village, Colorado, USA.
97. The International Association of Forensic Toxicologists. Reference blood level list of therapeutic and toxic substances, 2004.
98. R. C. Baselt. Disposition of Toxic Drugs and Chemicals in Man, 8 edition, 2008 Biomedical Publications: Foster City, California.